XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCENDIA PURCHASE AGREEMENT (Tables)
 9 Months Ended
Sep. 30, 2022
Restructuring Cost and Reserve [Line Items]  
SCHEDULE OF BUSINESS ACQUISITION, PRO FORMA INFORMATION

 

     2022   2021   2022   2021 
     Three Months Ended   Nine Months Ended 
     September 30,   September 30, 
     2022   2021   2022   2021 
Net Revenue    $13,044,571   $7,452,902   $36,454,704   $21,826,180 
Net Loss    $(1,529,252)  $(2,189,798)  $(3,193,078)  $(4,800,211)
Scendia Biologics LLC [Member]  
Restructuring Cost and Reserve [Line Items]  
SCHEDULE OF PURCHASE CONSIDERATIONS

The total purchase consideration, subject to typical post-closing adjustments, as determined by the Company was as follows:

 

Consideration  Equity Shares   Dollar Value 
Fair value of Sanara common shares issued   291,686   $6,032,066 
Cash consideration        1,238,423 
Fair value of contingent earnout consideration        3,000,000 
Total purchase consideration       $10,270,489 
SCHEDULE OF PURCHASE CONSIDERATION ON FAIR VALUE OF ASSETS ACQUIRED

Description  Amount 
Cash  $201,406 
Net working capital (excluding cash)   1,294,499 
Fixed assets, net   42,300 
Noncontrolling interest in Sanara Biologics, LLC   2,638 
Customer relationships   7,155,000 
Deferred tax liabilities   (1,702,890)
Goodwill   3,277,536 
Net assets acquired  $ 10,270,489